{"entity":{"id":"thomas-bachelot","kind":"person","name":"Thomas Bachelot","aka":[],"tldr":"Breast oncologist who led UNICANCER trials on brain metastases and hormone therapy resistance.","summary":"Thomas Bachelot is Head of Medical Oncology at Centre Léon Bérard in Lyon, part of the UNICANCER network. His specialisms are breast cancer, brain metastases and endocrine therapy. He led LANDSCAPE, the trial of lapatinib with capecitabine for brain metastases, and the TAMRAD and PADA-1 collaborations within UNICANCER's breast group. His papers include the GINECO randomised phase II trial of everolimus combined with tamoxifen in hormone receptor-positive metastatic breast cancer after aromatase inhibitors, the BELLE-3 phase 3 trial of buparlisib plus fulvestrant after mTOR inhibition, and the PANACEA trial of pembrolizumab plus trastuzumab in trastuzumab-resistant HER2-positive breast cancer. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bachelot%20T%5BAuthor%5D%20breast"}],"tags":[],"related":[],"cancers":["breast-hr-positive","breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":["lapatinib"],"companies":["unicancer"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head of Medical Oncology, Centre Léon Bérard, Lyon","institutionId":"unicancer","specialisms":["Breast cancer","Brain metastases","Endocrine therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bachelot%20T%5BAuthor%5D%20breast"}],"papers":[{"title":"Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study","journal":"Journal of Clinical Oncology","year":2012,"doi":"10.1200/jco.2011.39.0708"},{"title":"Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial","journal":"The Lancet Oncology","year":2018,"doi":"10.1016/s1470-2045(17)30688-5"},{"title":"Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial","journal":"The Lancet Oncology","year":2019,"doi":"10.1016/s1470-2045(18)30812-x"}],"orcid":"0000-0002-0866-9484"},"route":"/people/thomas-bachelot/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"drug":[{"id":"lapatinib","kind":"drug","name":"Lapatinib","route":"/drugs/lapatinib/"}],"company":[{"id":"unicancer","kind":"company","name":"UNICANCER","route":"/companies/unicancer/"}],"institution":[{"id":"centre-leon-berard","kind":"institution","name":"Centre Léon Bérard","route":"/institutions/centre-leon-berard/"}]}}